Health · FDA
FDA Orders Optic Nerve Warning on All GLP-1 Drugs Including Ozempic and Zepbound
The agency cited a rare eye condition that can cause permanent vision loss; it could not identify how the drugs might cause it, ABC News and NBC News reported.

The FDA announced Monday that makers of GLP-1 drugs must add a warning about a potential increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION, a rare condition in which reduced blood flow to the optic nerve can cause sudden, permanent vision loss, ABC News and NBC News reported. The requirement covers drugs including Ozempic, Wegovy, Mounjaro and Zepbound.
The review began after a 2024 JAMA Ophthalmology study linked semaglutide to the condition. ABC reported that the agency reviewed 126 clinical trials covering more than 134,000 patients and identified 15 probable cases, 10 in people taking GLP-1 drugs and five in the placebo group, an incidence of 6.4 versus 3.8 per 100,000 person-years. Both outlets said FDA scientists could not identify a mechanism.
Novo Nordisk told ABC it “continues to believe the data do not establish a cause-and-effect relationship.” NBC reported that spokespeople for Novo Nordisk and Eli Lilly each called patient safety a top priority.
Patients who notice sudden vision changes should contact a health care professional right away, ABC reported. An ophthalmologist told NBC patients should not stop their medications over the risk.
Sources
- ABC News (Good Morning America), Nov. 9, 2026: FDA requirement, trial analysis, incidence figures, company statements <https://www.goodmorningamerica.com/wellness/story/fda-orders-new-warning-ozempic-wegovy-glp-1-137981627>
- NBC News (via NBC 6 South Florida), Nov. 9, 2026: FDA requirement, mechanism, 2024 study, patient advice <https://www.nbcmiami.com/news/health/fda-warning-glp-rare-eye-condition-sudden-blindness/3885753/>
This article was drafted with AI writing tools from the sources listed, checked by a review pass, supervised by the paper’s editors and published by Daniel Varrone. Corrections: editor@monochromechronicles.com
More from Health
Recommended Reading
About this story: Compiled by the The Monochrome Chronicles desk from the sources listed above. Our standards · Report an error · Follow on YouTube